Cargando…
Azacytidine sensitizes acute myeloid leukemia cells to arsenic trioxide by up-regulating the arsenic transporter aquaglyceroporin 9
BACKGROUND: The therapeutic efficacy of arsenic trioxide (As(2)O(3)) in acute myeloid leukemia (AML) is modest, which is partly related to its limited intracellular uptake into the leukemic cells. As(2)O(3) enters cells via the transmembrane protein aquaglyceroporin 9 (AQP9). Azacytidine, a demethyl...
Autores principales: | Chau, David, Ng, Karen, Chan, Thomas Sau-Yan, Cheng, Yuen-Yee, Fong, Bonnie, Tam, Sidney, Kwong, Yok-Lam, Tse, Eric |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4431177/ https://www.ncbi.nlm.nih.gov/pubmed/25953102 http://dx.doi.org/10.1186/s13045-015-0143-3 |
Ejemplares similares
-
Feasibility of oral arsenic trioxide treatment for acute promyelocytic leukemia during hemodialysis
por: Au, Wing-Yan, et al.
Publicado: (2012) -
Arsenic transport by zebrafish aquaglyceroporins
por: Hamdi, Mohamad, et al.
Publicado: (2009) -
The Development and Clinical Applications of Oral Arsenic Trioxide for Acute Promyelocytic Leukaemia and Other Diseases
por: Chin, Lynn, et al.
Publicado: (2022) -
Oral arsenic trioxide for treating acute promyelocytic leukaemia: Implications for its worldwide epidemiology and beyond
por: Kumana, Cyrus R., et al.
Publicado: (2022) -
Resurrection of Oral Arsenic Trioxide for Treating Acute Promyelocytic Leukaemia: A Historical Account From Bedside to Bench to Bedside
por: Kumana, Cyrus R., et al.
Publicado: (2020)